Recursion (RXRX) and Exscientia plc (EXAI) have each received overwhelming approval from their shareholders for the proposed combination between Recursion and Exscientia. The transaction is expected to close on November 20, 2024, subject to the satisfaction or waiver of the remaining customary closing conditions. “The overwhelming support from both Recursion and Exscientia shareholders further validates our strong rationale for this business combination, and we look forward to closing the transaction next week,” said Chris Gibson, Ph.D., Co-Founder and CEO of Recursion who will continue as the CEO of the combined company following closing. “We look forward to bringing together Recursion’s biological and chemical exploration and mapping capabilities with Exscientia’s molecular design and automated chemistry synthesis capabilities to accelerate the discovery of better drugs for patients.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RXRX:
- Recursion Pharmaceuticals Reports Q3 2024 Earnings and Strategic Milestones
- Closing Bell Movers: AppLoving up 29% after Q3 earnings beat
- Recursion Pharmaceuticals reports Q3 EPS (34c), consensus (35c)
- Recursion Pharmaceuticals Advances Drug Discovery and Partnerships
- Cathie Wood’s ARK Investment buys 106K shares of Recursion Pharmaceuticals today
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
